Annex 1 - The Brave New World of Aseptic Regulatory Compliance
Challenge from the Client
After six years in review, the final emergence of Annex 1 in August 2022 has either been a consolidation of accepted practice and wisdom, or a rude awakening for many! However, it is universally accepted that it is the greatest single change to the regulatory approach in decades. As Annex 1 deals with products made in Europe, or products intended for Europe, it is likely to have a significant international reach.
Indeed, the narrative within Annex 1 has already been adopted by PIC/S and with close ties to the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) it will undoubtedly have a global reach. The regulatory bodies have also indicated a harsh stance on the implementation date. The regulatory view emerging is that the contents of the Annex should not be a surprise at this stage. Many companies are waking up to the realization that existing facilities of a certain vintage may not comply with the new requirements. And time is running out.
Our Approach & Solution
Our approach is holistic. We don’t simply find gaps in compliance; we work alongside our clients every step of the way to provide comprehensive solutions. IPS brings a unique blend of operational expertise, regulatory exposure, and expert technical knowledge to provide real support in not just identifying gaps, but closing them.
Our team of experts developed a unique Annex 1 Gap Analysis Tool that assists in systematically analyzing all aspects of a facility, including operational processes, against the new requirements. This tool is structured to provide a single source of knowledge related to the facility’s ‘state of readiness’. Once the gaps have been identified using this tool, our team aids in the process of meeting compliance. This could include utilizing IPS resources to provide assistance with sourcing and procurement of new equipment. Our goal is to serve as a trusted advisor from start to finish.
The Results
The Annex 1 Gap Analysis Tool has been deployed to help half a dozen clients in the Americans and in Europe reach compliance. This tool, combined with our unique expertise global resources, and end-to-end support, has been extremely effective in helping our clients both address and close the gaps in compliance.
Related Molecules
Mobile Modular Vaccine Facility
Read MoreDeliver a modular vaccine facility capable of being relocated anywhere in the world with minimal host facility requirements.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
Clinical Aseptic Spray Drying Facility Project
Read MoreIPS utilized the Inceptioneering process and expertise in aseptic spray drying technology for manufacturing APIs for formulation and filling.
Replacement Powder Mill for Pharmaceutical Client
Read MoreAfter a previous remediation attempts from other consultants failed, IPS was brought in to solve our client’s excess temperature problems in their new milling equipment.
Potent Processing on Antiquated Equipment
Read MoreIPS experts provided the latest technical solutions to retrofit a facility to improve manufacturing processes.
Modular Design, Construction and Installation of QC Labs
Read MoreA copy/paste modular build from the UK to Spain that overcame hurdles from the UK’s decision to leave the European Union.
Design of an Award-Winning, Fully Integrated Dual Sterile Filtration Unit, With In-situ Integrity Testing and Elimination of Contamination Routes
Read MoreIPS experts designed a filter skid system to eliminate contamination risks related to manual operations.
Innovative Commercial-Scale Parenteral Fill/Finish Facility
Read MoreUsing Facility of the Future design principles, IPS designed a world-class, flexible, 490,000sf. facility.
3D Modelling and Laser Scanning
Read More3D laser scanning used to coordinate and design a new PTW generation skid and pipework connections within an existing operating facility.
Next Generation Propellant Technology for Pharmaceutical MDI Applications
Read MoreIPS provided technical and site master planning expertise enabling new commercial opportunities within the MDI market sector.
Antibody Drug Conjugation Commercial Manufacturing
Read MoreApplied first class design tools and industry specific experiences to develop a greenfield site for commercial ADC manufacturing.
Mammalian Cell Culture to COVID-19 Vaccine Adjuvant in 3 weeks
Read MoreSoon after the COVID-19 outbreak, our client's direction shifted quickly from a mammalian cell culture facility to a COVID-19 vaccine adjuvant production facility.
Gene Therapy Facility
Read MoreOur client needed an efficient design for their gene biologics plant within an existing building with limited space for air handlers and mechanical equipment.
Large-Scale Bulk Manufacturing Facility
Read MoreIPS built a new greenfield facility in Ireland for bulk biologics manufacturing with single-use technology under an extremely aggressive timeline.
Single-Use Mammalian Cell Culture Facility - Vial to Vial
Read MoreOur challenge was to design a biologics manufacturing launch facility within an existing shell & office building.
Fast-Track Project Delivery Model
Read MoreA vaccine manufacturer and distributor needed IPS’ expertise to meet an aggressive timeline for expansion of their production facility.
Detailed Process Piping
Read MoreSupporting a client’s dynamic business requirements to produce a near-fabrication-level model to reduce schedule time.
Water For Injection (WFI) Generation System Design for a Global CMO Biotechnology Facility for the Manufacture of mAb/Recombinant Protein
Read MoreBiotech CMO client needed an n+1 redundant system to handle increased WFI demand, while reducing operating costs.
Commercial Manufacturing of Autologous Muscle Derived Cell (AMDC) products
Read MoreApplying industry-leading knowledge and expertise to support CGMP-compliant manufacturing process scale-up.
Clinical Phage Production - Design/Build/Qualify
Read MoreA start-up biotech company needed to generate phase 1 and phase 2 clinical material for a phage-based therapy on an aggressive timeline and tight budget.
Largest Single-use Based mAb Facility in the World
Read MoreOur CMO client wanted to do something radically different by creating a multiproduct, multiscale mAb facility that could flex upstream capacity in 2000L intervals.
